SWOG clinical trial number
CTSU/E5204

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation

Closed
Phase
Abbreviated Title
Rectal Ph III oxaliplatin, 5-FU, leucovorin +\- bevacizumab
Activated
04/15/2006
Closed
04/29/2009
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Leucovorin + 5-FU Oxaliplatin Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (nttp://www.ctsu.org/) for more information.

Publication Information Expand/Collapse

2016

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (Bev) for patients (pts) with stage II or III rectal cancer receiving pre-operative chemoradiation: E5204 coordinated by the Eastern Cooperative Oncology Group

AB Benson;N Meropol;P Catalano;F Zhao;E Sigurdson;A Chakravarthy;S Hamilton;P Flynn;K Kiel;C Leichman;N Petrelli;F Sinicrope;J Tepper;J Sloan;J Meyerhardt;L Wagner;P O'Dwyer Journal Clinical Oncology 34, 2016 (suppl; abstr 3616); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
83%
Open
Phase